Browsing Tag
Novo Nordisk
79 posts
Pfizer thought it secured Metsera—then Novo Nordisk crashed the party with a bigger bid
Novo Nordisk just challenged Pfizer’s Metsera deal with a $9B rival bid. Find out how this could reshape the weight-loss drug landscape in 2025.
Why Viking Therapeutics (NASDAQ: VKTX) is gaining momentum before ObesityWeek 2025 reveals
Find out how Viking Therapeutics is positioning its obesity drug VK2735 for success as it readies data reveals at major 2025 medical conferences.
Hims & Hers Health plunges 11% after CEO Andrew Dudum offloads $11m in stock
Shares of Hims & Hers Health fell 11% after CEO Andrew Dudum disclosed a multimillion-dollar stock sale. Find out what’s worrying investors next.
Novo Nordisk seeks FDA nod for Mim8 — how will this impact hemophilia treatment and NVO stock?
Novo Nordisk files FDA application for Mim8 in hemophilia A. Learn how flexible dosing and trial data could redefine the bleeding disorder market.
Are Novo Nordisk layoffs, FDA scrutiny of Hims & Hers, and UnitedHealth profit squeeze reshaping the healthcare sector?
Novo Nordisk layoffs, Hims & Hers FDA warning, and UnitedHealth earnings headwinds shake the healthcare sector. See what investors need to know.
Eli Lilly commits $6.5bn to new Houston manufacturing site for small molecule APIs
Eli Lilly invests $6.5B in a Houston API facility to scale orforglipron and small molecule drugs, creating 4,600+ jobs and reshaping U.S. pharma supply.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
Pfizer to buy Metsera in $7.3bn obesity drug deal, challenging Lilly and Novo
Pfizer’s $7.3B Metsera takeover could reshape the GLP-1 obesity drug race and challenge Eli Lilly and Novo Nordisk’s dominance in weight loss treatments.
GLP-1 receptor agonists show promise in cutting death and heart risk in psoriasis patients
Discover how GLP-1 drugs may slash death and heart risks in psoriasis patients, reshaping care strategies beyond skin treatment.